Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) Shares Outstanding (Diluted Average) (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $16.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 9.79% to $16.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Dec 2025, up 9.79% year-over-year, with the annual reading at $16.7 million for FY2025, 9.79% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $16.7 million in Q4 2025 for Coya Therapeutics, roughly flat from $16.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $16.7 million in Q3 2025 to a low of $2.6 million in Q1 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $11.0 million across 4 years, with a median of $12.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 292.4% in 2023 and later rose 9.79% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $2.6 million in 2022, then surged by 292.4% to $10.2 million in 2023, then skyrocketed by 49.93% to $15.2 million in 2024, then rose by 9.79% to $16.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for COYA at $16.7 million in Q4 2025, $16.7 million in Q3 2025, and $16.7 million in Q2 2025.